September 1, 2015Open Access

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

Key Points

Key points are not available for this paper at this time.

Abstract

Adjuvant erlotinib did not prolong DFS in patients with EGFR-expressing NSCLC or in the EGFRm-positive subgroup. Further evaluation of erlotinib is warranted in the EGFRm-positive subgroup.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Kelly et al. (Tue,) studied this question.

synapsesocial.com/papers/69dcc30ed4d0de07d11339bd https://doi.org/https://doi.org/10.1200/jco.2015.61.8918

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Reduced-dose versus full-dose erlotinib for advanced EGFR-mutant non-small cell lung carcinoma (NSCLC): A retrospective analysis.2015 · 6 citations